UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` - - - - - - - - - - - - - - - - -
`
`PFIZER, INC. and SAMSUNG BIOEPIS
`CO., LTD.,
`
` Petitioners, Case No.:
` IPR2017-01488
` IPR2017-01489
` Patent 6,407,213
`-vs.-
`GENENTECH, INC.,
` Patent Owner.
`
`- - - - - - - - - - - - - - - - -
` Case IPR2017-02139 has been joined with this
`proceeding.
` Case IPR2017-02140 has been joined with this
`proceeding.
` Deposition of IAN A. WILSON, D.Phil.
` La Jolla, California
` Saturday, April 21, 2018
` 9:07 a.m.
`Job No.: 185272
`Pages: 1 - 299
`Reported by: Tricia Rosate, RDR, RMR, CRR, CCRR
`CSR No. 10891
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`1 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` - - - - - - - - - - - - - - - - -
`
`PFIZER, INC. and SAMSUNG BIOEPIS
`CO., LTD.,
`
` Petitioners, Case No.:
` IPR2017-01488
` IPR2017-01489
` Patent 6,407,213
`-vs.-
`GENENTECH, INC.,
` Patent Owner.
`
`- - - - - - - - - - - - - - - - -
` Case IPR2017-02139 has been joined with this
`proceeding.
` Case IPR2017-02140 has been joined with this
`proceeding.
` Deposition of IAN A. WILSON, D.Phil.
` La Jolla, California
` Saturday, April 21, 2018
` 9:07 a.m.
`Job No.: 185272
`Pages: 1 - 299
`Reported by: Tricia Rosate, RDR, RMR, CRR, CCRR
`CSR No. 10891
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`1 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`2
`
`Deposition OF IAN A. WILSON, D.Phil, held at:
` Residence Inn by Marriott
` 8901 Gilman Drive
` La Jolla, California 92037
` (858) 587-1770
`
` Pursuant to Notice, before Tricia Rosate, RDR,
`RMR, CRR, CCRR, Certified Shorthand Reporter No.
`10891 in and for the State of California.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`2 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`3
`
` A P P E A R A N C E S
`ON BEHALF OF THE PETITIONER PFIZER, INC.:
` BENJAMIN LASKY, ESQ.
` KIRKLAND & ELLIS, LLP
` 601 Lexington Avenue
` New York, New York 10022
` (212) 446-6415
` blasky@kirkland.com
` -and-
` SHARICK NAQI, ESQ.
` KIRKLAND & ELLIS, LLP
` 300 North LaSalle
` Chicago, Illinois 60654
` (312) 862-3235
` sharick.naqi@kirkland.com
`
`ON BEHALF OF THE PETITIONER CELLTRION INC.:
` ROBERT V. CERWINSKI, ESQ.
` GOODWIN PROCTER, LLP
` 620 Eighth Avenue
` New York, New York 10018
` (212) 459-7240
` rcerwinski@goodwinlaw.com
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`3 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`4
`
` A P P E A R A N C E S (Continued)
`ON BEHALF OF THE PETITIONER SAMSUNG BIOEPIS:
` AMIT THAKORE, ESQ.
` WHITE & CASE, LLP
` 1221 Avenue of the Americas
` New York, New York 10020-1095
` (212) 819-2692
` athakore@whitecase.com
`
`ON BEHALF OF THE PATENT OWNER GENENTECH, INC.:
` ANDREW J. DANFORD, ESQ.
` WILMER CUTLER PICKERING HALE and DORR, LLP
` 60 State Street
` Boston, Massachusetts 02109
` (617) 526-6806
` andrew.danford@wilmerhale.com
` -and-
` NORA Q.E. PASSAMANECK, ESQ.
` WILMER CUTLER PICKERING HALE and DORR, LLP
` 1225 17th Street
` Suite 2600
` Denver, Colorado 80202
` (720) 274-3152
` nora.passamaneck@wilmerhale.com
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`4 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`5
`
` A P P E A R A N C E S (Continued)
`ALSO PRESENT:
` SARAH MILLER, The Videographer
` TRACI ROPP, Genentech
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`5 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`6
`
` C O N T E N T S
`EXAMINATION OF IAN A. WILSON, D.Phil. PAGE
`By Mr. Lasky ....................... 8, 146, 280
`By Mr. Cerwinski ....................... 268
`By Mr. Danford ....................... 270
`
` E X H I B I T S
` (Attached to transcript)
`WILSON DEPOSITION EXHIBIT PAGE
`Exhibit 1194 "Humanization of a mouse 187
` anti-human IgE antibody: a
` potential therapeutic for
` IgE-mediated allergies"
`
`Exhibit 1195 "Applications and Engineering 217
` of Monoclonal Antibodies"
`
` P R E V I O U S L Y M A R K E D E X H I B I T S
` Exhibit 1001 Exhibit 1055
` Exhibit 1002 Exhibit 1071
` Exhibit 1003 Exhibit 1125
` Exhibit 1021 Exhibit 1193
` Exhibit 1034 Exhibit 2041
` Exhibit 1052
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`6 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:02:00
`09:02:00
`09:02:00
`09:05:53
`09:05:55
`09:05:58
`09:06:07
`09:06:20
`09:06:30
`09:07:33
`09:07:36
`09:07:38
`09:07:41
`09:07:45
`09:07:50
`09:07:51
`09:07:53
`09:07:55
`09:07:57
`09:07:59
`09:08:01
`09:08:03
`09:08:07
`09:08:09
`09:08:10
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`7
`
` LA JOLLA, CALIFORNIA; SATURDAY, APRIL 21, 2018
` 9:07 A.M. - 6:15 P.M.
` - - - -
` THE VIDEOGRAPHER: Here begins Tape No. 1 in
`the videotaped deposition of Dr. Ian Wilson in the
`matter of Pfizer vs. Genentech and Celltrion vs.
`Genentech, Case No. IPR2017-01486-01489 [sic] and
`Case No. IPR2017-01373-01374.
` Today's date is April 21, 2018. The time on
`the video monitor is 9:07 a.m.
` The videographer today is Sarah Miller,
`representing Planet Depo.
` This video deposition is taking place at
`8901 Gilman Drive, La Jolla, California.
` Will counsel please voice identify
`themselves and state whom they represent.
` MR. LASKY: My name's Ben Lasky from
`Kirkland & Ellis. I represent Pfizer.
` With me today from Kirkland & Ellis is
`Sharick Naqi.
` MR. CERWINSKI: I'm Robert Cerwinski. I'm
`with Goodwin Procter, LLP, and I represent Celltrion,
`petitioner.
` MR. THAKORE: Amit Thakore from White & Case
`representing petitioner Samsung Bioepis.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`7 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:08:17
`09:08:17
`09:08:17
`09:08:22
`09:08:24
`09:08:25
`09:08:29
`09:08:31
`09:08:43
`09:08:43
`09:08:43
`09:08:43
`09:08:43
`09:08:44
`09:08:46
`09:08:52
`09:08:53
`09:08:53
`09:08:54
`09:08:55
`09:08:56
`09:08:58
`09:09:00
`09:09:01
`09:09:01
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`8
`
` MR. DANFORD: Andrew Danford from WilmerHale
`representing patent owner, Genentech and the witness,
`and I'm joined today by Nora Passamaneck of
`WilmerHale and Traci Ropp of Genentech.
` THE VIDEOGRAPHER: Okay. The court reporter
`today is Tricia Rosate representing Planet Depo.
` Will the reporter please swear in the
`witness.
` IAN A. WILSON, D.Phil.,
` having been first duly sworn, testified as follows:
` EXAMINATION
`BY MR. LASKY:
` Q Good morning, Dr. Wilson.
` I just need to say something for the record.
`The first case number, 2017-01488, and that's my
`fault, my handwriting. So --
` Good morning.
` A Good morning.
` Q Could you please state your full name for
`the record.
` A Ian Andrew Wilson.
` Q And have you had your deposition taken
`before?
` A Yes.
` Q How many times?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`8 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:09:03
`09:09:05
`09:09:05
`09:09:07
`09:09:08
`09:09:11
`09:09:14
`09:09:19
`09:09:23
`09:09:24
`09:09:26
`09:09:27
`09:09:30
`09:09:31
`09:09:32
`09:09:34
`09:09:38
`09:09:39
`09:09:40
`09:09:41
`09:09:48
`09:09:48
`09:09:50
`09:09:51
`09:09:53
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`9
`
` A I can't remember how many. About three or
`four.
` Q Okay. And were they all in connection with
`expert witness work?
` A Yes.
` Q Okay. How many times have you previously
`served as an expert witness in a litigation or
`patent office proceeding?
` A Could you explain?
` Q Sure. Well, let's start with a
`district court action.
` Have you ever served as an expert in a court
`action?
` A One. One time.
` Q Okay. And who were you retained by in that
`case?
` A WilmerHale.
` Q Okay. And who was the --
` Well, first of all, was Genentech the party
`that you were representing there?
` A I don't think so.
` Q Okay. Do you know who the party was?
` A I can't remember.
` Q Okay. Was the party the patent owner?
` Well, strike that.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`9 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:09:55
`09:09:57
`09:10:00
`09:10:04
`09:10:08
`09:10:09
`09:10:10
`09:10:11
`09:10:13
`09:10:23
`09:10:23
`09:10:25
`09:10:26
`09:10:29
`09:10:31
`09:10:31
`09:10:34
`09:10:34
`09:10:41
`09:10:43
`09:10:44
`09:10:47
`09:10:49
`09:10:52
`09:10:55
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`10
`
` Was this a patent case?
` A It's such a long time ago, I can't -- I
`don't actually remember the details of the case. I
`actually destroy the documents, and I destroy it from
`my memory, too. So --
` Q Fair enough.
` Do you know what the issues were that you
`were giving an opinion on in that case?
` A It had to do with epitopes on -- on a
`receptor.
` Q And was it relating to a therapeutic
`product?
` A As far as I -- I recall, yes.
` Q Do you recall what the product was?
` A No.
` Q Okay. And you were deposed in that case?
` A Yes.
` Q Okay. Other than that case, have you ever
`been involved in a case in the district court or in
`any court?
` A No.
` Q All right. Have you ever served as an
`expert witness previously in an action before the
`U.S. Patent and Trademark Office?
` A In what sense? I don't really --
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`10 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:10:57
`09:10:59
`09:11:00
`09:11:02
`09:11:06
`09:11:09
`09:11:10
`09:11:11
`09:11:13
`09:11:15
`09:11:19
`09:11:20
`09:11:24
`09:11:32
`09:11:34
`09:11:35
`09:11:37
`09:11:44
`09:11:45
`09:11:50
`09:11:51
`09:11:53
`09:11:55
`09:11:55
`09:11:58
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`11
`
` You -- I'm not understanding some of the
`questions.
` Q Okay. Sure. So you understand that the
`proceeding that you're here for today is an
`inter partes review in the U.S. Patent and Trademark
`Office?
` Do you understand that?
` A I understand it now.
` Q Oh, okay. Okay. Well, why don't you tell
`me. What other cases have you been involved in as an
`expert witness?
` A They've -- they'e largely been to do -- to
`do with -- cases to do with -- with patents. By and
`large, I think it's been patents.
` I had one other case that had noth- -- that
`was -- that was a separate issue that was just a
`dispute between parties on some scientific grounds.
` Q Okay. Have you ever previously been
`retained by Genentech in a legal matter?
` A Yes.
` Q And -- and what -- what did that involve?
` A That involved -- similar to dealing with
`patents.
` Q And was it relating to the product
`Herceptin?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`11 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:12:00
`09:12:01
`09:12:02
`09:12:02
`09:12:03
`09:12:04
`09:12:06
`09:12:12
`09:12:15
`09:12:17
`09:12:19
`09:12:20
`09:12:26
`09:12:27
`09:12:28
`09:12:32
`09:12:34
`09:12:37
`09:12:37
`09:12:41
`09:12:43
`09:12:51
`09:12:53
`09:12:55
`09:12:56
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`12
`
` A Other than this case?
` Q Yes.
` A No.
` Q Okay.
` A Not -- not that I remember.
` Q Okay. So the other case that you worked
`with -- worked on with Genentech, what product was
`involved in that case?
` A I can't remember what -- what those were.
` Q Okay. Was -- was that in the U.S. or
`somewhere else?
` A U.S. Or those -- those are Brazilian
`proceedings as well.
` Q Okay. And when was this?
` A That's been ongoing for the last year or so.
` Q Okay. And were you -- have you had a
`deposition taken in that case?
` A No.
` Q Okay. Other than in litigation or in the
`patent office, have you ever been retained by
`Genentech as a consultant?
` A Not to the -- not to my knowledge.
` Q Have you ever received funding from
`Genentech?
` A Funding from -- personally or for my lab?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`12 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:12:58
`09:13:05
`09:13:06
`09:13:07
`09:13:07
`09:14:05
`09:14:07
`09:14:15
`09:14:24
`09:14:26
`09:14:47
`09:14:49
`09:14:57
`09:14:57
`09:15:00
`09:15:02
`09:15:03
`09:15:04
`09:15:09
`09:15:12
`09:15:13
`09:15:14
`09:15:15
`09:15:17
`09:15:19
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`13
`
` Q For your lab.
` A No.
` Q Okay. And personally?
` A No.
` Q Okay. The declarations --
` I've handed you two documents, Dr. Wilson.
`One is marked Exhibit 2041 in IPR2017-01488, and one
`is marked Exhibit 2041 in IPR2017-01489.
` These are the two declarations that you've
`submitted in these proceedings?
` A I just wanted to make sure my signature is
`on there.
` Yes, they are.
` Q Okay. Is it fair to say that the two
`declarations are substantively identical in terms of
`their content?
` A As far as I remember, yes.
` Q Okay. At the time you signed them, you
`believed them to be true and accurate to the best of
`your knowledge; is that right?
` A Yes, I did.
` Q Okay. Is there anything that you now
`realize is -- was in error or that you want to
`change?
` A No. I -- I -- there's one or two typos,
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`13 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:15:25
`09:15:29
`09:15:32
`09:15:33
`09:15:35
`09:15:36
`09:15:36
`09:15:40
`09:15:40
`09:15:42
`09:15:44
`09:15:50
`09:15:56
`09:15:57
`09:16:12
`09:16:12
`09:16:14
`09:16:15
`09:16:17
`09:16:20
`09:17:30
`09:17:31
`09:17:33
`09:17:35
`09:17:37
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`14
`
`very minor things, a missing word, a missing comma, a
`missing exponent on the 9. But as far as substance
`are concerned, no.
` Q Okay. Well, as we go through, if there's
`anything you see that you --
` A Sure.
` Q -- need to change in terms of typos --
` A Sure.
` Q -- please let me know.
` Now, at the back of each of your
`declarations, you will see that there is a list of
`the materials that -- well, it's a "Materials
`Considered" list.
` Do you see that?
` A Exhibit B?
` Q Exhibit B. Yes.
` A I see that.
` Q Okay. And did you review and consider each
`of the documents in that "Materials Considered" list
`in each of your declarations?
` A I don't -- I don't remember every single one
`of them, but I recognize most of these, yes.
` Q Okay. And you read and understood all of
`these references before providing your declaration;
`is that right?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`14 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:17:39
`09:17:44
`09:17:49
`09:17:54
`09:17:56
`09:18:02
`09:18:03
`09:18:16
`09:18:18
`09:18:20
`09:18:24
`09:18:29
`09:18:32
`09:18:34
`09:18:37
`09:18:39
`09:18:42
`09:18:44
`09:18:57
`09:18:58
`09:19:07
`09:19:07
`09:19:09
`09:19:14
`09:19:18
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`15
`
` A I -- to the extent that I was required to --
`that I was required to for my deposition, yes -- for
`my declaration.
` Q Okay. Do you know if there's any documents
`here that you didn't review completely?
` A "Completely" meaning --
` Q Like, read it from start to finish.
` A I think I've -- I've opened most of the
`documents, whether -- and -- and skimmed through
`them. I -- I can't -- there's so many documents
`here, I can't -- I can't recall every single document
`that's in this particular list as to when I reviewed
`it.
` Q Okay. Is it fair to say, though, if it's
`listed here, it's something that you opened,
`considered relevant enough to consider it, and place
`it on your "Materials Considered" list?
` MR. DANFORD: Objection to form.
` THE WITNESS: Most of the -- the things I --
`I recognize, yes.
`BY MR. LASKY:
` Q Is there anything you're aware of that you
`considered that's missing from this list?
` A Whoa.
` Q And I guess I'm asking if you're aware of
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`15 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:19:20
`09:19:21
`09:19:22
`09:19:28
`09:19:32
`09:19:33
`09:19:33
`09:19:37
`09:19:43
`09:19:45
`09:19:46
`09:19:48
`09:19:49
`09:19:53
`09:19:55
`09:19:58
`09:19:59
`09:20:04
`09:20:07
`09:20:08
`09:20:08
`09:20:09
`09:20:12
`09:20:14
`09:20:19
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`16
`
`it.
` A I'm not aware of any. I'd have to go
`through and -- and check, but I'm not aware of -- of
`any. Most of the papers, of course, I recognize
`right away, and --
` Yes.
` Q Okay. Before -- I want to focus on the time
`before you submitted your declarations up to when you
`submitted them.
` How much time did you spend on the case?
` A Before I submitted the declaration?
` Q Right. Up to the date that you submitted
`the declaration. How much time would you have
`submitted on --
` A Many, many hours.
` Q How many -- how many would you --
` A I haven't added them up yet, but it would be
`tens of hours.
` Q Tens of hours?
` A Yeah. Uh-huh.
` Q Less than 100?
` A I couldn't say if it was less than 100 or
`more than 100, but it was a -- a large number of
`hours.
` Q Okay. And did you read the '213 patent in
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`16 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:20:25
`09:20:26
`09:20:28
`09:20:31
`09:20:35
`09:20:37
`09:20:39
`09:20:41
`09:20:42
`09:20:44
`09:20:46
`09:20:48
`09:20:49
`09:20:51
`09:20:56
`09:20:57
`09:20:58
`09:20:58
`09:21:00
`09:21:02
`09:21:03
`09:21:06
`09:21:08
`09:21:11
`09:21:13
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`17
`
`preparation of your declaration?
` A Yes.
` Q Okay. Do you know how much time you spent
`reviewing that patent?
` A Again, it -- it would -- it's hard to
`estimate because I've reviewed it multiple times. So
`I've read --
` It would be a number of hours.
` Q Okay. And have you read it again since
`you've provided your declaration?
` A I've looked through it. Yeah.
` Q And do you consider yourself to be familiar
`with its contents?
` MR. DANFORD: Objection to form.
` THE WITNESS: I'm generally familiar with
`it.
`BY MR. LASKY:
` Q Okay. And did -- did you review the claims
`that are at the end of the '213 patent?
` A Yes, I did.
` Q Okay. And do you consider yourself to
`understand what the claims mean in providing your
`opinions in this case?
` A As far --
` I believe I understand the claims, yes.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`17 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:21:14
`09:21:19
`09:21:21
`09:21:24
`09:21:56
`09:21:58
`09:22:07
`09:22:14
`09:22:15
`09:22:16
`09:22:16
`09:22:18
`09:22:20
`09:22:23
`09:22:24
`09:22:25
`09:22:27
`09:22:27
`09:22:34
`09:22:36
`09:22:39
`09:22:43
`09:22:46
`09:22:46
`09:22:48
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`18
`
` Q Okay. Other than counsel for Genentech,
`have you had any discussions with anyone in
`connection with this case?
` A No.
` Q I've handed you a copy of what's been marked
`as Pfizer Exhibit 1001 in the 01488 IPR.
` Is this the '213 patent that's at issue in
`this case?
` A Was that a question?
` Q Yeah. Is it -- yeah.
` Just for the record, is this the '213 patent
`that you considered for this case?
` A It says '213 at the top, so I'll take it as
`'213. Yes.
` Q Okay. Do you recognize it, though, as
`the -- as the patent that you have provided opinions
`on in this case?
` A Yes.
` Q Okay. I just want to -- you've -- you've
`provided some opinions that you disagree with
`Dr. Foote and Dr. Riechmann and their opinions
`regarding the '213 patent; right?
` A Correct.
` Q I just want to try to get some points of
`agreement, though. And I want to focus on the date
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`18 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:22:54
`09:23:00
`09:23:03
`09:23:08
`09:23:13
`09:23:15
`09:23:15
`09:23:18
`09:23:22
`09:23:33
`09:23:36
`09:23:41
`09:23:42
`09:23:47
`09:23:47
`09:23:49
`09:23:53
`09:23:58
`09:24:00
`09:24:03
`09:24:05
`09:24:06
`09:24:06
`09:24:13
`09:24:27
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`19
`
`before the invention that's described in the '213
`patent. And I know there's some dispute about that
`date. So I just want to focus on the time before the
`invention was made. Is that okay? I'm going to ask
`you questions about that.
` A Yeah. Sure.
` Q Okay. Now, before that invention date of
`the '213 patent, you would agree that it was known
`that overexpression of the HER2 protein led to a poor
`prognosis in cancer, including breast cancer; right?
` MR. DANFORD: Objection. Outside the scope.
` THE WITNESS: If you're asking if there were
`papers on that protein, the answer would be yes.
`BY MR. LASKY:
` Q Right. You don't dispute, though, that it
`was known that overexpression of HER2 led to a
`particularly poor prognosis in breast cancer prior to
`the '213 patent invention; right?
` MR. DANFORD: Objection. Outside the scope.
` THE WITNESS: I believe that there was some
`correlation. Yes.
`BY MR. LASKY:
` Q And prior to the '213 patent invention, work
`had been done to identify murine antibodies that
`would target the HER2 receptor; is that right?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`19 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:24:30
`09:24:30
`09:24:33
`09:24:37
`09:24:43
`09:24:46
`09:24:47
`09:24:51
`09:24:58
`09:25:02
`09:25:03
`09:25:06
`09:25:08
`09:25:39
`09:25:41
`09:25:47
`09:25:52
`09:25:54
`09:25:55
`09:25:56
`09:25:59
`09:26:00
`09:26:01
`09:26:04
`09:26:07
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`20
`
` A I believe that is the case. Yes.
` Q And so, for example, in the Hudziak,
`H-u-d-z-i-a-k, reference, the authors described the
`generation of a number of antibodies, mouse
`antibodies, against the HER2 receptor; is that right?
` A That is correct.
` Q And Hudziak and co-authors, prior to the
`'213 patent invention, had tested those mouse
`antibodies for their ability to stem cell
`proliferation; right?
` A Could you show me the patent to -- show me
`the paper to refresh my memory.
` Q Okay. Sorry.
` Dr. Wilson, I've handed you a copy of what's
`been marked as Pfizer Exhibit 1021 in the 01488 IPR,
`and this is the Hudziak reference I was referring to.
` Have you reviewed this for purposes of this
`case?
` A Yes, I have.
` Q Okay. And it's published in March 1989; is
`that right?
` A That is correct.
` Q And that's before the '213 patent invention;
`is that right?
` A Yes.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`20 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:26:08
`09:26:14
`09:26:21
`09:26:27
`09:26:31
`09:26:34
`09:26:35
`09:26:36
`09:26:42
`09:26:50
`09:26:50
`09:26:53
`09:26:56
`09:27:00
`09:27:08
`09:27:08
`09:27:09
`09:27:13
`09:27:17
`09:27:21
`09:27:25
`09:27:27
`09:27:32
`09:27:32
`09:27:33
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`21
`
` Q Okay. And -- and if you -- if you look at
`the introduction, Hudz- -- in the last paragraph of
`the introduction, the authors note that, to
`facilitate investigation of the normal role of the
`HER2 gene product --
` Oh, I'm sorry.
` A So where are we?
` Q In the introduction to the paper and the
`last paragraph.
` A Okay.
` Q They note that, to facilitate investigation
`of the normal biological role of the HER2 gene
`product, they prepared monoclonal antibodies against
`the extracellular domain of the p185 HER2 protein.
` Do you see that?
` A Yes, I see that.
` Q And then one of those monoclonal antibodies,
`the 4D5, was characterized in more detail and shown
`to inhibit in vitro proliferation of human
`breast canc- -- tumor cells overexpressing HER2 and
`furthermore to increase the sensitivity of these
`cells to the cytotoxic effects of TNF-alpha.
` Do you see that?
` A Yes, I see that.
` Q And then, if you look over to page 11 of the
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`21 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:27:36
`09:27:43
`09:27:52
`09:27:58
`09:28:01
`09:28:03
`09:28:04
`09:28:05
`09:28:10
`09:28:13
`09:28:15
`09:28:15
`09:28:17
`09:28:21
`09:28:25
`09:28:29
`09:28:41
`09:28:46
`09:28:47
`09:28:49
`09:28:55
`09:28:56
`09:28:56
`09:29:05
`09:29:09
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`22
`
`exhibit and table 1 of the reference, you see there
`is a test of certain mono- -- the -- the ability of
`certain monoclonal antibodies to inhibit tumor
`cell -- tumor cell line proliferation by
`anti-HER2 [sic] monoclonal antibodies.
` Do you see that?
` A I do.
` Q And the 4D5 antibody was shown to have
`the -- the greatest effect of relative cell
`proliferation.
` Do you see that?
` A That is correct.
` Q Okay. And -- and so back to my original
`question. Before the '213 patent invention, Hudziak
`and colleagues had shown that the 4D5 antibody was
`able to inhibit cell proliferation through targeting
`the HER2 receptor; is that right?
` MR. DANFORD: Objection to form.
` THE WITNESS: It was shown to inhibit the
`proliferation of the SK-BR-3 breast tumor cells.
`Yes.
`BY MR. LASKY:
` Q And the 4D5 antibody that was being tested
`by Hudziak was a mouse antibody; is that right?
` A Yes.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`22 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:29:09
`09:29:12
`09:29:17
`09:29:22
`09:29:25
`09:29:26
`09:29:27
`09:29:30
`09:29:32
`09:29:32
`09:29:35
`09:29:48
`09:29:48
`09:29:53
`09:29:57
`09:29:57
`09:29:59
`09:30:01
`09:30:07
`09:30:15
`09:30:19
`09:30:23
`09:30:24
`09:30:25
`09:30:25
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`23
`
` Q And prior to the '213 patent invention, it
`was known that mouse antibodies had limited value as
`human therapeutics due to the likelihood of
`immunogenicity; is that right?
` MR. DANFORD: Objection to form.
` THE WITNESS: There was a concern that you
`might get a reaction against a mouse antibody if you
`give it to a human. Yes.
`BY MR. LASKY:
` Q Okay. Prior to the '213 patent invention,
`scientists investigated ways to avoid or minimize the
`immunogenetic -- immugenic -- immunogenic potential
`of murine monoclonal antibodies; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: Yes.
`BY MR. LASKY:
` Q And you don't dispute in your declaration
`that, prior to the '213 patent invention, there was a
`motivation to try to develop the 4D5 monoclonal
`antibody as a human therapeutic agent; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: I don't really know if I quite
`understand the question.
`BY MR. LASKY:
` Q Okay.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`23 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:30:26
`09:30:29
`09:30:31
`09:30:34
`09:30:35
`09:30:36
`09:30:40
`09:30:45
`09:30:46
`09:30:47
`09:30:47
`09:30:48
`09:30:53
`09:31:01
`09:31:04
`09:31:05
`09:31:07
`09:31:07
`09:31:08
`09:31:09
`09:31:12
`09:31:13
`09:31:16
`09:31:20
`09:31:25
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`24
`
` A I understand, but I don't understand the
`intent of the question is really --
` Q Oh, okay. I mean, there's no intent. I'm
`just trying to --
` A No. There's -- there's many -- there's
`many -- many antibodies you could actually have
`looked at. 4D4 -- 4D5 was an antibody that had been
`identified.
` Q Okay.
` A Yep.
` Q And in -- and Hudziak, at least, had shown
`4D5 to be the -- the most effective at
`antiproliferative activity against HER2
`overexpressing breast cancer cells; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: In the study that they did.
`BY MR. LASKY:
` Q Uh-huh.
` A I don't know if that -- if there could have
`been a better antibody, but in the part they looked
`at, yes.
` Q Okay. So my question is: Prior to the '213
`patent invention, you would agree that, based on
`Hudziak's data, there was a motivation to investigate
`the 4D5 antibody as a human therapeutic agent against
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`24 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:31:29
`09:31:33
`09:31:34
`09:31:36
`09:31:38
`09:31:41
`09:31:46
`09:31:46
`09:31:48
`09:31:54
`09:31:57
`09:32:05
`09:32:06
`09:32:07
`09:32:09
`09:32:11
`09:32:13
`09:32:13
`09:32:24
`09:32:32
`09:32:38
`09:32:43
`09:32:46
`09:32:46
`09:32:54
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`25
`
`HER2 overexpressing breast cancer; right?
` MR. DANFORD: Objection. Asked and
`answered.
` THE WITNESS: That antibody was one of many,
`but that is -- Hudziak identified that as a
`potential.
`BY MR. LASKY:
` Q And with respect to that 4D5 antibody,
`though, again, it was known that, as a murine
`antibody, it would be likely to be ineffective as a
`human therapeutic agent due to the immunogenic
`potential; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: One can't tell until one did,
`actually, the experiment, but that would have been a
`concern from -- generally from mouse antibodies.
`BY MR. LASKY:
` Q Okay. Now, prior to the '213 patent
`invention, scientists had investigated ways to reduce
`the immunogenic potential of murine monoclonal
`antibodies, one way being to develop a chimeric
`antibody; right?
` A That is correct.
` Q And the chimeric antibody was made by
`placing the murine variable domain on a human
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`25 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:32:59
`09:33:00
`09:33:03
`09:33:08
`09:33:16
`09:33:20
`09:33:25
`09:33:28
`09:33:29
`09:33:29
`09:33:32
`09:33:35
`09:33:36
`09:33:41
`09:33:44
`09:33:49
`09:33:50
`09:33:53
`09:33:54
`09:33:54
`09:34:02
`09:34:06
`09:34:11
`09:34:15
`09:34:15
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`26
`
`constant do
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
